Source comparison
Egrifta vs Other Peptides: Comparison Table
Tesamorelin occupies a unique regulatory and mechanistic niche. The table below compares Egrifta to other peptides investigated or approved for metabolic applications, clarifying where tesamorelin fits in the broader landscape. | Peptide | Primary Mechanism |
This comparison does not assign a generated winner or score.
- Tesamorelin occupies a unique regulatory and mechanistic niche. The table below compares Egrifta to other peptides investigated or approved for metabolic applications, clarifying where tesamorelin fits in the broader landscape.
- | Peptide | Primary Mechanism | FDA Approval Status | Target Population | Typical Dose | Key Metabolic Effect | Professional Assessment ||—|—|—|—|—|—|| Tesamorelin (Egrifta) | GHRH agonist. Stimulates endogenous GH secretion | FDA-approved (2010) for HIV lipodystrophy | HIV patients with excess visceral fat | 2mg SC daily | Selective VAT reduction; modest triglyceride lowering; no appetite suppression | Only FDA-approved peptide for body composition in HIV; requires continuous use; glucose monitoring mandatory || Semaglutide (Wegovy) | GLP-1 receptor agonist. Delays gastric emptying, reduces appetite | FDA-approved for obesity (2021) | Adults with BMI ≥30 or ≥27 + comorbidity | 2.4mg SC weekly | Mean 15% body weight reduction; mixed fat loss (VAT + SAT + lean mass) | Superior total weight loss; broader indication; appetite-driven mechanism limits adherence in some || Tirzepatide (Mounjaro, Zepbound) | Dual GIP/GLP-1 agonist | FDA-approved for obesity (2023) | Adults with BMI ≥30 or ≥27
- Bottom Line: Tesamorelin is the only GHRH agonist with FDA approval and robust Phase 3 data for a metabolic indication. GLP-1 agonists produce greater total weight loss but lack selectivity for visceral fat. Other GHRH peptides (sermorelin, CJC-1295) lack regulatory approval and comparable clinical validation.